These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33597205)

  • 21. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
    Bruce IN; van Vollenhoven RF; Morand EF; Furie RA; Manzi S; White WB; Abreu G; Tummala R
    Rheumatology (Oxford); 2023 Apr; 62(4):1526-1534. PubMed ID: 36018235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
    Jayne D; Rovin B; Mysler EF; Furie RA; Houssiau FA; Trasieva T; Knagenhjelm J; Schwetje E; Chia YL; Tummala R; Lindholm C
    Ann Rheum Dis; 2022 Apr; 81(4):496-506. PubMed ID: 35144924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
    Tang W; Tummala R; Almquist J; Hwang M; White WI; Boulton DW; MacDonald A
    Clin Pharmacokinet; 2023 May; 62(5):655-671. PubMed ID: 37148484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
    Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2021 Dec; 80(10):988-994. PubMed ID: 33216191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.
    Jayne D; Rovin B; Mysler E; Furie R; Houssiau F; Trasieva T; Knagenhjelm J; Schwetje E; Tang W; Tummala R; Lindholm C
    Lupus Sci Med; 2023 Aug; 10(2):. PubMed ID: 37607780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL; Tummala R; Mai TH; Rouse T; Streicher K; White WI; Morand EF; Furie RA
    J Clin Pharmacol; 2022 Sep; 62(9):1094-1105. PubMed ID: 35352835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S; Ehreiser L; Anders J; Anders HJ
    Front Immunol; 2022; 13():999704. PubMed ID: 36211360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
    Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
    Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
    Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
    Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications.
    Larsen ML; Skouboe MK; Mogensen TH; Laursen AL; Deleuran B; Troldborg A; Rasch MNB
    Am J Case Rep; 2024 Sep; 25():e944505. PubMed ID: 39245905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
    Wallace DJ; Atsumi T; Daniels M; Hammer A; Meizlik P; Quasny H; Schwarting A; Zhang F; Roth DA
    Lupus; 2022 Nov; 31(13):1649-1659. PubMed ID: 36206400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.
    Neupane B; Shukla P; Slim M; Martin A; Petri M; Bertsias GK; Kim AHJ; Fanouriakis A; Levy RA; Chauhan D; Ballew N
    Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37147022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus.
    Cingireddy AR; Ramini N; Cingireddy AR
    Cureus; 2024 Jul; 16(7):e63966. PubMed ID: 39104974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
    Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
    Khanna D; Denton CP; Assassi S; Kuwana M; Allanore Y; Domsic RT; Kleoudis C; Xu J; Csomor E; Seo C; Albulescu M; Tummala R; Al-Mossawi H; Kalyani RN; Del Galdo F
    Clin Exp Rheumatol; 2024 Aug; 42(8):1635-1644. PubMed ID: 39152751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.